Pharmacist-run teriparatide clinic

American Journal of Health-System Pharmacy

Volumn 60, Issue 21, 2003, Pages 2247-2249

  Stroup, Jeffrey ^a   Kane, Michael P ^b   Busch, Robert S ^c  

^a Internal Medicine and Endocrinology

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c Endocrine Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN LISPRO; PARATHYROID HORMONE[1-34];

ARTICLE; BONE PAIN; CHILL; HUMAN; INJECTION SITE PAIN; LEG CRAMP; OSTEOPOROSIS; PHARMACIST; PRIORITY JOURNAL; BONE DENSITY; DRUG EFFECT; ECONOMICS; FEMALE; HEALTH CARE QUALITY; HOSPITAL PHARMACY; METHODOLOGY; PATIENT EDUCATION; POSTMENOPAUSE OSTEOPOROSIS; PROFESSIONAL STANDARD; SUBCUTANEOUS DRUG ADMINISTRATION;

BONE DENSITY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT EDUCATION; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PROFESSIONAL ROLE; QUALITY OF HEALTH CARE; TERIPARATIDE;

EID: 1542577685     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.21.2247     Document Type: Article

References (4)

1. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. wmv.nof.org/osteoporosis/stats.htm (accessed 2003 May 27) .
2. Siris ES, Miller PD, Barrett-Connor E et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286:2815-26.
3. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIH consensus statement, http://consensus.nih.gov/cons/111/ 111_statement.pdf (accessed 2003 Jul 23).
4. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344:1434-41.